ScreenerHero

ELAN Elanco Animal Health Incorporated

NYSE · US · Healthcare · Drug Manufacturers - Specialty & Generic · elanco.com
22.51USD+1.67%Mkt Cap: 11.25B $P/E: —

Elanco Animal Health Incorporated, an animal health company, innovates, develops, manufactures, and markets products for pets and farm animals worldwide. The company offers pet health products, such as parasiticides, vac…

Industry Peers

Drug Manufacturers - Specialty & Generic
Screen all
MRK
Merck KGaA
$64.30BUSDP/E 25.0
TAK
Takeda Pharmaceutical Company Limited
$56.90BUSD
TEVA
Teva Pharmaceutical Industries Limited
$46.26BUSDP/E 66.1
HLN
Haleon plc
$38.79BUSDP/E 18.0
ZTS
Zoetis Inc.
$29.51BUSDP/E 11.7
ZOE
Zoetis Inc.
$28.27BUSDP/E 12.1
UTHR
United Therapeutics Corporation
$23.01BUSDP/E 19.2
VTRS
Viatris Inc.
$20.24BUSD
SOBI
Swedish Orphan Biovitrum AB (publ)
$14.14BUSDP/E 110.6
NBIX
Neurocrine Biosciences, Inc.
$14.66BUSDP/E 21.1
IPN
Ipsen S.A.
$12.60BUSDP/E 22.8
RDY
Dr. Reddy's Laboratories Limited
$10.26BUSDP/E 28.0
KRK
Krka, d. d.
$8.59BUSDP/E 19.2
ALKS
Alkermes plc
$7.17BUSDP/E 112.5
AMRX
Amneal Pharmaceuticals, Inc.
$7.09BUSDP/E 41.5
HIMS
Hims & Hers Health, Inc.
$6.92BUSD
LNTH
Lantheus Holdings, Inc.
$6.54BUSDP/E 24.3
KNSA
Kiniksa Pharmaceuticals International, plc
$5.87BUSDP/E 77.1
APTX
Apotex Health Corp.
$5.17BUSD
INDV
Indivior Pharmaceuticals, Inc.
$4.25BUSDP/E 12.9

Key Statistics

Company
Market Cap11.25B USD
Enterprise Value14.76B USD
Revenue (TTM)5.02B USD
Gross Profit2.59B USD
Net Income (TTM)-232.00M USD
Revenue/Share10.09 USD
Last Price22.51 USD
Fiscal Year EndDec 2025
MR QuarterJun 2026
Employees9.4K
CountryUS
SectorHealthcare
IndustryDrug Manufacturers - Specialty & Generic
ISIN—
Valuation
P/E (Trailing)—
P/E (Forward)17.23
PEG4.04
EV/EBITDA14.66
EV/Revenue2.94
P/S2.20
P/B1.68
EPS (TTM)-0.41
EPS (Forward)1.28
52W Range
19.4036% of range27.98
52W High27.98 USD
52W Low19.40 USD
Profitability
Gross Margin54.99%
Oper. Margin8.63%
EBITDA Margin20.06%
Profit Margin-4.92%
ROE-3.54%
ROA-1.74%
Growth
Revenue Growth10.20%
Earnings Growth440.50%
Cash Flow & Leverage
Operating CF560.00M USD
CapEx (TTM)276.00M USD
FCF Margin16.47%
FCF Yield7.35%
Net Debt3.70B USD
Net Debt/EBITDA3.68
Balance Sheet
Debt/Equity0.61
Current Ratio2.05
Quick Ratio0.91
Book Value/Sh13.19 USD
Cash/Share1.06 USD
Dividends
Fwd Div Rate—
Trail. Div Rate0.00 USD
Div. Yield0.00%
5Y Avg Yield—
Payout Ratio0.00%
Ex-Div Date—
Pay Date—
Analyst Consensus
Rating1.5 (Buy)
Strong BuyBuyHoldSellStr. Sell
Target (Mean)31.00 USD
Upside (mean)+37.7%
Target Range26.00 USD – 34.00 USD
26.00+37.7% to mean34.00
# Analysts13
Ownership
Shares Out.499.62M
Float495.40M
Insiders1.21%
Institutions115.25%
Short Interest
Short Ratio6.5d
Short % Float10.12%
Short % Out.6.37%
Shares Short31.81M
Short (prev mo.)29.72M
Technical
SMA 5023.76 (-5.2%)
SMA 20023.80 (-5.4%)
Beta1.68
S&P 52W Chg14.58%
Avg Vol (30d)5.24M
Avg Vol (10d)5.79M
Technical Indicators
RSI (14)44.7
MACD-0.4472
MACD Signal-0.4539
MACD Hist.+0.0067
BB Upper23.71 USD
BB Middle22.71 USD
BB Lower21.71 USD
BB Width8.82%
ATR (14)0.7501 USD
Vol Ratio (20d)0.86x